Search

everythinglearnresearchcommunity

for

Search:↓

The user shared progress pictures showing significant hair regrowth from using finasteride, RU58841, and liquid minoxidil, emphasizing the importance of consistency. They noted that RU58841, a research chemical not FDA-approved, was effective when applied topically but warned of potential heart-related side effects.

A user created a tracker for hair loss treatments in clinical development, including compounds like Dermaliq, RU58841, and Pyrilutamide. The tracker updates with new information and allows filtering by conditions like androgenetic alopecia (AGA) and alopecia areata (AA).

The conversation warns about taking information on pyrilutamide with skepticism, suggesting that many may not have the genuine product. It advises to wait for FDA approval for reliable information.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

The conversation is about testing the effectiveness of RU58841 for hair loss, with the user planning to increase their dose to 30 mg per day along with 20 mg of Minoxidil. The test results showed approximately 70 mg/ml, which the user considers a good result.

A user falsely claimed to use 2.5mg of dutasteride by using someone else's photo, which actually showed results from finasteride. The conversation discusses the challenges and skepticism around hair loss treatments like dutasteride and finasteride.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation discusses hair loss treatments, focusing on the use of topical minoxidil, microneedling, finasteride, and dutasteride, while debating the role of testosterone and DHT in hair loss. It also touches on the potential liver health impacts of these treatments and the genetic sensitivity of hair follicles to androgens.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

The user is unsure if their hair appears fuller due to a haircut or actual regrowth, but believes there is increased density and small new hairs. They are using 1 mg finasteride daily, 2.5 mg minoxidil daily, and Nizoral frequently for hair loss treatment.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The conversation is about a user defending their hair loss progress photos against accusations of being fake, explaining changes in hair color and texture due to dyeing and straightening. The user shares their treatment timeline, using dutasteride and minoxidil, and addresses side effects and skepticism from others.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

The conversation is about determining if a purchased Minoxidil product is genuine. The user shared images for verification.

The conversation is about the impressive hair density and hairline of a person, with users attributing it to good genetics and joking about the lack of hair loss despite stress. Specific hair loss treatments like Minoxidil, Finasteride, or RU58841 are not discussed.

A user created a free AI-powered hair transplant simulator to help visualize post-transplant results, seeking feedback and offering it as a tool for clinics. Users discussed its usefulness, limitations, and the requirement for email and phone verification to prevent abuse.

The conversation discusses skepticism about the effectiveness and formulation of a $10 RU58841 gel from a Korean brand, questioning if ethanol is used to hold the active compounds. Concerns are raised about the feasibility of selling it at such a low price.

Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.

PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.

RU58841 from AliExpress and its legitimacy. Users discuss purchasing RU58841 from different sources and the effectiveness of the product.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

A user reported a 50% increase in testosterone after 18 months of taking dutasteride for hair loss. The conversation includes skepticism about the reliability of single testosterone tests and questions about estrogen levels.

KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.

Hair transplants in Turkey often involve high-volume, low-quality procedures with untrained staff, leading to unreliable results. Many users recommend choosing experienced surgeons who perform fewer surgeries per day, even if it means paying more in countries like Switzerland, Spain, or Thailand.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Most people using finasteride, minoxidil, or dutasteride for hair loss experience maintenance or regrowth, but they often don't discuss it publicly. Online forums may not accurately represent the typical success rates, as satisfied users rarely share their positive outcomes.

The conversation is about finding a trustworthy supplier for Pyrilutamide, a hair loss treatment. The user previously purchased RU58841 from Anagenic and is considering them for Pyrilutamide.

Ultrasound imaging can predict hair shedding and assess hair growth stages by analyzing hair follicle characteristics. The conversation also discusses using ultrasound for personal hair analysis and mentions the potential use of infrared emission for hair treatment.